Channel
@hitnews_telegram
On this record: Topic · Growth · Engagement · Posts · Citations · Cite this entry
818subscribers
+33 since we began measuring on 7 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1002005869857 |
|---|---|
| Type | Channel |
| Username | @hitnews_telegram |
| Created | Between 1 November 2023 and 31 May 2024 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 8 August 2026 |
| Last confirmed live | 15 September 2026 |
| Measurements held | 7 |
| Confirmed unchanged | 1 time, most recently 15 September 2026 |
| On Telegram | t.me/hitnews_telegram |
National news — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 20 September 2026 and assigned it the closest of 31 fixed categories, at 42% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 15 Sept 2026, 05:59 | 818 | +2 |
| 8 Sept 2026, 01:54 | 816 | +18 |
| 29 Aug 2026, 23:23 | 798 | +14 |
| 23 Aug 2026, 12:16 | 784 | -3 |
| 16 Aug 2026, 08:27 | 787 | +2 |
| 8 Aug 2026, 01:46 | 785 | no change |
| 7 Aug 2026, 17:55 | 785 | first reading |
20 posts held, back to 27 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 7 August 2026. An engagement rate over an empty window would be a number about nothing.
HIT Daily Brief PM (2026/08/07) ☑️[주식] 알테오젠·리가켐 상승…파마리서치 실적 올라도 4%↓ https://hitnews.co.kr/news/articleView.html?idxno=78261 ☑️'공시 먼저, 설명은 근거 있게'…바이오 IR·홍보도 새 국면 https://hitnews.co.kr/news/articleView.html?idxno=78237 ☑️나갈 돈 나갔다, 이제 들어올 차례…드디어 시작된 '탁소텔'의 시간 https://hitnews.co.kr/news/articleView.html?idxno=78234 ☑️외형이냐 체질 개선이냐, 비만약 강자 '릴리 VS 노보'의 다른 길 https://hitnews.co.kr/news/articleView.html?idxno=78228 ☑️리가켐,…
Signed kim minji
HIT Daily Brief AM (2026/08/07) ☑️기술이전 11조 쌓은 알테오젠...코스닥 승강제 '수혜주' 되나 https://www.hitnews.co.kr/news/articleView.html?idxno=78235 ☑️콘테라파마 가르는 부광…RNA분리법인, 플랫폼 3종 자생력 채우나 https://www.hitnews.co.kr/news/articleView.html?idxno=78238 ☑️[주식] '인도 뚫은 자큐보'…온코닉테라퓨틱스 22% 급등 https://hitnews.co.kr/news/articleView.html?idxno=78232 ☑️일반약 비타민 '액상+정제' 이중제형 길 열렸다 https://hitnews.co.kr/news/articleView.html?idxno=78227 ☑️잇치는 굳건, …
HIT Daily Brief PM (2026/08/06) ☑️[주식] '인도 뚫은 자큐보'…온코닉테라퓨틱스 22% 급등 https://hitnews.co.kr/news/articleView.html?idxno=78232 ☑️자큐보, 신청 2개월만에 인도서 품목허가 획득 https://hitnews.co.kr/news/articleView.html?idxno=78222 ☑️디엑스앤브이엑스, 남미 공공보건기관과 첫 KRNA 물질이전계약 https://hitnews.co.kr/news/articleView.html?idxno=78219 ☑️파로스아이바이오, 국책과제로 IRP2 항암제 개발 착수 https://hitnews.co.kr/news/articleView.html?idxno=78217 ☑️일반약 비타민 '액상+정제' 이중제형 길 열…
Signed kim minji
HIT Daily Brief AM (2026/08/06) ☑️바이오 옥석가리기? 실패 없는 기업만 찾는다면 '옥'은 없다 https://www.hitnews.co.kr/news/articleView.html?idxno=78212 ☑️어려울 때 GC녹십자 2분기 살린 건, 끈끈한 '피의 힘' https://www.hitnews.co.kr/news/articleView.html?idxno=78193 ☑️'818이냐 828이냐'…중국은 세포치료제 갈림길을 먼저 묻는다 https://www.hitnews.co.kr/news/articleView.html?idxno=78213 ☑️[주식] 비만치료제 개발 중단 우려에 '디앤디파마텍' 18%↓ https://hitnews.co.kr/news/articleView.html?idxno=78210 ☑…
HIT Daily Brief PM (2026/08/05) ☑️[주식] 비만치료제 개발 중단 우려에 '디앤디파마텍' 18%↓ https://hitnews.co.kr/news/articleView.html?idxno=78210 ☑️ALT-B4 또 한 건 했다, 알테오젠 총 5219억원 기술수출 계약 https://hitnews.co.kr/news/articleView.html?idxno=78189 ☑️'실패 역사' 쌓이게 된 바이오 공시…"성공보다 실패 먼저 볼 수도" https://hitnews.co.kr/news/articleView.html?idxno=78186 ☑️하반기 매출 불붙여라 "서정진 셀트리온 회장 직접 해외법인 순회" https://hitnews.co.kr/news/articleView.html?idxno=78191 ☑…
Signed kim minji
🏢 ALT-B4 또 한 건 했다, 알테오젠 총 5219억원 기술수출 계약 알테오젠이 글로벌 제약사와 자사의 하이브로자임(Hybrozyme) 플랫폼 기술 관련 최대 3억6500만 달러(약 5219억원) 규모의 라이선스 계약을 체결했다. 회사는 하이브로자임 플랫폼 기술이 적용된 재조합 인간 히알루로니다제 ALT-B4를 활용한 바이오의약품 피하주사(SC) 제형 개발 및 상업화를 위한 독점적 라이선스 계약을 체결했다고 5일 밝혔다. 계약 규모는 선급금 및 개발·허가·상업화 마일스톤을 포함해 최대 3억 6500만 달러로 알테오젠은 ALT-B4가 적용된 제품의 첫 상업 판매 이후 발생하는 순매출액에 대해 별도의 판매 로열티를 수취할 예정이다. 🔗https://www.hitnews.co.kr/news/articleView.html?idxno=781…
Signed kim minji
HIT Daily Brief AM (2026/08/05) ☑️'신약의 힘' 빛난 전통제약 빅5, 외형·수익성 모두 개선 https://www.hitnews.co.kr/news/articleView.html?idxno=78188 ☑️'적자→흑자' 지엘팜텍 바꾼 더블유사이언스, 다음 그림은 IPO https://www.hitnews.co.kr/news/articleView.html?idxno=78182 ☑️'메이드 인 식약처' 간 오가노이드', OECD 표준화 노린다 https://www.hitnews.co.kr/news/articleView.html?idxno=78187 ☑️[주식]큐리언트·앱클론, 증권가 추천에 주가 쭉쭉 키웠다 https://hitnews.co.kr/news/articleView.html?idxno=78184 ☑️올…
HIT Daily Brief PM (2026/08/04) ☑️[주식]큐리언트·앱클론, 증권가 추천에 주가 쭉쭉 키웠다 https://hitnews.co.kr/news/articleView.html?idxno=78184 ☑️올릭스, 탈모치료제 'OLX104C' 호주 1b상 투약 완료 https://hitnews.co.kr/news/articleView.html?idxno=78173 ☑️유한 2Q 책임질 히어로, 올해도 등장한 '렉라자 기술료' https://hitnews.co.kr/news/articleView.html?idxno=78159 ☑️'레즈디프라+위고비 'MASH' 새 치료법으로? 시장이 큰다 https://hitnews.co.kr/news/articleView.html?idxno=78155 ☑️중증 재생불량성 빈혈약 '로미…
Signed kim minji
HIT Daily Brief AM (2026/08/04) ☑️가치 25조원? 한올 면역치료제 '아이메로프루바트' 왜 주목받나 https://www.hitnews.co.kr/news/articleView.html?idxno=78156 ☑️늘리고 붙이고 바꾸고…바이오, 황반변성 강자 '아일리아' 넘어서기 경쟁 https://www.hitnews.co.kr/news/articleView.html?idxno=78157 ☑️GC녹십자웰빙, 하반기 희비 '라이넥+이니보'에 달렸다 https://www.hitnews.co.kr/news/articleView.html?idxno=78160 ☑️[주식] 릴리 덕분에? 펩트론 상한가 속…티앤알바이오팹 급락 https://www.hitnews.co.kr/news/articleView.html?idxno=7…
HIT Daily Brief PM (2026/08/03) ☑️[주식] 릴리 덕분에? 펩트론 상한가 속…티앤알바이오팹 급락 https://www.hitnews.co.kr/news/articleView.html?idxno=78158 ☑️보로노이, 홍콩서 항암신약물질 'VRN11' 1b/2상 IND 승인받아 https://hitnews.co.kr/news/articleView.html?idxno=78134 ☑️HLB파나진-주가이 파마바디 리서치, 싱가포르 PNA 유통 독점 계약 https://hitnews.co.kr/news/articleView.html?idxno=78135 ☑️[IPO] 인제니아, 일반청약 '3.09대 1' 마무리…18일 상장 준비 막바지 https://hitnews.co.kr/news/articleView.html?id…
Signed kim minji
HIT Daily Brief AM (2026/08/03) ☑️정부가 메스 댄 바이오공시 개편 "현실은 쉽지 않다" 이유는? https://www.hitnews.co.kr/news/articleView.html?idxno=78123 ☑️식약처가 제기한 '조인트스템' 2차전, 이긴다고 '무엇'이 남을까 https://www.hitnews.co.kr/news/articleView.html?idxno=78127 ☑️"십수년 노하우 담긴 'iRAC' 기반 바이오 기업으로 재도약" https://www.hitnews.co.kr/news/articleView.html?idxno=78126 ☑️삼성·셀트 사로잡은 지투지바이오..."항체 SC로 승부본다" https://www.hitnews.co.kr/news/articleView.html?idxno=…
HIT Daily Brief PM (2026/07/31) ☑️[주식] 셀비온 19% 급등…대웅제약·네이처셀 약세 https://hitnews.co.kr/news/articleView.html?idxno=78108 ☑️킴리아 따라 잡은 CAR-T 치료신약 '림카토'… 첫 투약 언제부터 https://hitnews.co.kr/news/articleView.html?idxno=78074 ☑️네이처셀, 조인트스템 FDA pre-BLA 미팅 신청 https://hitnews.co.kr/news/articleView.html?idxno=78086 ☑️익수다 테라퓨틱스, ADC 후보물질 'IKS04' FDA 허가 https://hitnews.co.kr/news/articleView.html?idxno=78078 ☑️셀트리온 "옴리클로, 오말리주맙…
Signed kim minji
Showing the 12 most recent of 20 posts we hold for @hitnews_telegram. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Named by 2 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 15 September 2026 — this entry's latest reading, not the date you are reading this.
“바이오헬스 히트뉴스” (@hitnews_telegram), 818 subscribers as measured 15 September 2026. Telegram Register, tgregister.com/channel/hitnews_telegram.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.